Preclinical

Rezolute

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

Lead Product(s): RZ402

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

RZ402 demonstrated an excellent ADME (absorption, distribution, metabolism and excretion) profile, and moderate renal clearance with plasma levels remained above EC50 for 24 hours after dosing, consistent with a daily oral dose regimen.

Samsung Bioepis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

SB15 received the green light from health authorities in eight countries, including phase three clinical trials in South Korea and the United States. SB15 is a biosimilar candidate of Regeneron Pharmaceuticals' Eylea, to treat age-related (wet) macular degeneration (AMD).

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

InMed Releases CBN Preclinical Results in Glaucoma

Lead Product(s): Cannabinol

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

Combination of CBN and elevated pressure, within the same time period, resulted in a high level of cell survival in a dose dependent fashion. CBN was superior to both CBD and THC under identical testing conditions.

CDR Life

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy

Lead Product(s): Antibody fragment-based therapeutics

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: Undisclosed Upfront Cash: $494.0 million

Deal Type: Licensing Agreement May 13, 2020

Details:

Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

Lead Product(s): Cannabinol

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

With INM-088, an eye drop formulation of CBN, the Company is exploring the treatment for glaucoma, either as a prospective stand-alone or an adjunct therapy, and in other ocular diseases.

Suzhou Ribo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Suzhou Ribo Life Science Completes $66 Million C Round for siRNA Portfolio

Lead Product(s): RB-RQ007

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Capital Venture Capital Fund

Deal Size: $66.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing April 06, 2020

Details:

The funding is inted boost company's siRNA Portfolio.

SanBio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Sanbio and Ocumension Ink Pact For Research, Development of Innovative Stem Cell Therapies for Ophthalmic Diseases

Lead Product(s): SB623

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Ocumension

Deal Size: $71.0 million Upfront Cash: $6.0 million

Deal Type: Agreement April 01, 2020

Details:

Ocumension obtains exclusive rights from SanBio to develop and commercialize SB623 and MSC2 in Greater China for ophthalmic indications.

Ocugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

Lead Product(s): NR2E3-AAV

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

Data support nuclear hormone receptor gene NR2E3 as genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases and potentially serve as a broad-spectrum therapy.

Graybug Vision

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Graybug Vision Presents Preclinical Results for GB-401

Lead Product(s): GB-401

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2020

Details:

The study showed that GB-401 achieved sustained ocular drug levels and reduced IOP in experimental animal models after a single intravitreal or subconjunctival injection.